ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Post-marketing safety profile of palivizumab: a 20-year pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS).
Qing Yan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.